GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01359696
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute.., Detroit, Michigan, United States
🇫🇷Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo, Villejuif, France
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01356173
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 448
- Registration Number
- NCT01343966
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Pharmacology Research Inst, Newport Beach, California, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT01336465
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01335958
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01332604
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01301716
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01300247
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 674
- Registration Number
- NCT01296555
- Locations
- 🇺🇸
Univ of Chicago, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States
🇺🇸Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01292473
© Copyright 2024. All Rights Reserved by MedPath